RenovoRx Q2 2026: Record Revenue, Full Enrollment, and Cash Runway Through 2027
RNXT sits 78% above its 52-week low of $0.701 on elevated volume (3.3× avg).
Summary
RenovoRx reported record Q2 2026 revenue of $909,000, raised full-year guidance, and announced full enrollment in its Phase III TIGeR-PaC trial. The 10-Q confirms cash runway into the second half of 2027.
Key Events · Earnings and Guidance · RNXT
-
Record Q2 Revenue
Revenue of $909,000 for Q2 2026, up 61% sequentially and 115% year-over-year, driven by expansion of active commercial cancer centers to 21.
-
Full Enrollment in Phase III Trial
TIGeR-PaC trial fully enrolled; 78 of 86 required events have occurred as of August 11, 2026. Top-line data expected in the second half of 2027.
-
Cash Runway Extended
Cash and cash equivalents of $9.5 million as of June 30, 2026, expected to fund operations into the second half of 2027.
-
Nasdaq Compliance Deadline
Company has until December 28, 2026 to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
Analysis · RNXT · Life Sciences
RenovoRx delivered record Q2 revenue of $909,000, up 115% year-over-year, and raised full-year guidance. The company also announced full enrollment in its Phase III TIGeR-PaC trial. The 10-Q provides detailed financials showing $9.5 million in cash, sufficient to fund operations into the second half of 2027. The company remains non-compliant with Nasdaq's minimum bid price requirement, with a deadline of December 28, 2026 to regain compliance.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNXT was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.8M. The 52-week trading range was $0.70 to $1.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.